TD Asset Management Inc. Boosts Position in FibroGen, Inc (FGEN)

TD Asset Management Inc. boosted its position in shares of FibroGen, Inc (NASDAQ:FGEN) by 23.7% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 31,926 shares of the biopharmaceutical company’s stock after acquiring an additional 6,126 shares during the quarter. TD Asset Management Inc.’s holdings in FibroGen were worth $1,718,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of FGEN. Vanguard Group Inc. grew its holdings in FibroGen by 15.1% during the second quarter. Vanguard Group Inc. now owns 5,808,439 shares of the biopharmaceutical company’s stock valued at $187,612,000 after purchasing an additional 761,421 shares during the period. BlackRock Inc. grew its holdings in FibroGen by 12.3% during the second quarter. BlackRock Inc. now owns 5,001,406 shares of the biopharmaceutical company’s stock valued at $161,545,000 after purchasing an additional 546,587 shares during the period. FMR LLC grew its holdings in FibroGen by 96.9% during the second quarter. FMR LLC now owns 3,335,997 shares of the biopharmaceutical company’s stock valued at $107,753,000 after purchasing an additional 1,641,423 shares during the period. State Street Corp grew its holdings in FibroGen by 16.4% during the second quarter. State Street Corp now owns 1,763,387 shares of the biopharmaceutical company’s stock valued at $56,962,000 after purchasing an additional 248,922 shares during the period. Finally, Hillhouse Capital Management Ltd. grew its holdings in FibroGen by 75.0% during the second quarter. Hillhouse Capital Management Ltd. now owns 1,750,000 shares of the biopharmaceutical company’s stock valued at $56,525,000 after purchasing an additional 750,000 shares during the period. Institutional investors own 57.43% of the company’s stock.

In other news, CEO Thomas B. Neff sold 38,636 shares of the company’s stock in a transaction dated Thursday, September 14th. The stock was sold at an average price of $51.67, for a total value of $1,996,322.12. Following the completion of the transaction, the chief executive officer now owns 3,297,655 shares of the company’s stock, valued at $170,389,833.85. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider K Peony Yu sold 2,851 shares of the company’s stock in a transaction dated Thursday, September 14th. The stock was sold at an average price of $51.00, for a total value of $145,401.00. Following the completion of the transaction, the insider now directly owns 185,546 shares of the company’s stock, valued at approximately $9,462,846. The disclosure for this sale can be found here. In the last ninety days, insiders sold 397,131 shares of company stock valued at $21,109,380. Corporate insiders own 13.60% of the company’s stock.

Several analysts have issued reports on FGEN shares. Jefferies Group reissued a “buy” rating and set a $75.00 price target on shares of FibroGen in a report on Tuesday, September 12th. Mizuho reissued a “hold” rating and set a $61.00 price target on shares of FibroGen in a report on Thursday, November 9th. Stifel Nicolaus reissued a “buy” rating and set a $80.00 price target on shares of FibroGen in a report on Thursday, September 14th. ValuEngine lowered FibroGen from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Finally, BidaskClub lowered FibroGen from a “hold” rating to a “sell” rating in a report on Thursday. Two analysts have rated the stock with a sell rating, two have issued a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. FibroGen currently has a consensus rating of “Buy” and a consensus price target of $65.67.

FibroGen, Inc (FGEN) opened at $46.40 on Monday. The company has a current ratio of 10.83, a quick ratio of 10.83 and a debt-to-equity ratio of 0.16. FibroGen, Inc has a one year low of $19.25 and a one year high of $60.15.

ILLEGAL ACTIVITY WARNING: “TD Asset Management Inc. Boosts Position in FibroGen, Inc (FGEN)” was first posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.chaffeybreeze.com/2017/12/11/td-asset-management-inc-boosts-position-in-fibrogen-inc-fgen.html.

FibroGen Profile

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Institutional Ownership by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply